OTC : EGRX

Eagle Pharmaceuticals, Inc.

$0.06885 USD

$0.02 (35.27%)

Volume
837
Average Volume
3.88K
Market Capitalization
$905.9K
P/E Ratio
0.02
Dividend Yield
0.00%
Price Target
Year High
$3.87
Year Low
$0.05
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.70
Company Overview

OTC

Michael Graves

Drug Manufacturers - Specialty & Generic

Healthcare

EGRX

135

US

USD

https://www.eagleus.com

201 326 5300

269796108

0000827871

Liquidity Metrics

0.29

1.70

1.27

0.50

0.00

Sales & Valuation

$316.61M

0.00

0.00

0.03

2.38

Profitability

$2.73

$35.64M

11.26%

19.40%

17.39%

8.78%

P/E Metrics

0.02

0.00

0.00

Analyst Price Target & Rating

N/A

0/5

6 Analysts

%

Financial Health Scores

1.65

4/9

$100.62M

$404.82M

$152.78M

$35.33M

Key Metrics (TTM)

$13.14M

0.04

0.17

1.70

17.39%

15.51%

5413.96%

4598.50%

$33.46

195 days

Company Executives
Name Title
Valentin R. Curt Senior Vice President of Clinical Drug Development
Christopher Krawtschuk Chief Financial Officer and Principal Financial & Accounting Officer
Daniel O'Connor Executive Vice President, Chief Strategy Officer & Head of Corporate Development
Michael Graves CEO & Chairman
Poll Results

No votes yet today — be the first to share your view!

About Eagle Pharmaceuticals, Inc. (OTC:EGRX) Stock

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (P ... ONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Galera Therapeutics (NASDAQ:GRTX) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Review

2026-07-17 04:23:27

Profitability This table compares Galera Therapeutics and Eagle Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Eagle Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Galera Therapeutics and Eagle Pharmaceuticals"s top-line revenue, earnings per share and valuation. Gross

Frequently Asked Questions

What is the current Eagle Pharmaceuticals, Inc. (EGRX) stock price?

Eagle Pharmaceuticals, Inc.(OTC:EGRX) stock price is $0.06885 in the last trading session. During the trading session, EGRX stock reached the peak price of $3.87 while $0.0504 was the lowest point it dropped to. The percentage change in EGRX stock occurred in the recent session was 35.27% while the dollar amount for the price change in EGRX stock was $0.02.

EGRX's industry and sector of operation?

The OTC listed EGRX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of EGRX?

Valentin R. Curt | Senior Vice President of Clinical Drug Development
Christopher Krawtschuk | Chief Financial Officer and Principal Financial & Accounting Officer
Daniel O'Connor | Executive Vice President, Chief Strategy Officer & Head of Corporate Development
Michael Graves | CEO & Chairman
|

How many employees does EGRX have?

Number of EGRX employees currently stands at 135. EGRX operates from 50 Tice Boulevard, Woodcliff Lake, NJ 07677, US.

Link for EGRX official website?

Official Website of EGRX is: https://www.eagleus.com

How do I contact EGRX?

EGRX could be contacted at phone #201 326 5300 and can also be accessed through its website. EGRX operates from 50 Tice Boulevard, Woodcliff Lake, NJ 07677, US.

How many shares of EGRX are traded daily?

The average number of EGRX shares traded daily for last 3 months was 3.88K.

What is the market cap of EGRX currently?

The market value of EGRX currently stands at $905.9K with its latest stock price at $0.06885